Xoma Corporation

Igm Biosciences, Inc.

Xoma Technology Ltd.

University of California

Research Development Foundation

Igm Biosciences A/s

Stephen Fitzhugh Carroll

Mark Leslie White

Marc D Better

Gary M Studnicka

Jeremy Kam-kuen Ma

Arnold H Horwitz

Bruce Alan Keyt

David J Burke

Ramesh Baliga

Dane A Goff

Russell L Dedrick

Dean Ng

Jeremy K-k Ma

Leonard G Presta

David S Eisenberg

Fen Zhang

Lesa J Beamer

Leonard George Presta

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent hepatitis B virus antigen binding molecules and uses thereof

The present invention concerns IgA multi-specific binding molecules. In particular, the invention concerns multi-specific, including bispecific, binding molecules comprising IgA heavy chain sequences, and methods for their preparation and use.

IgA multi-specific binding molecules

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

Immunotoxins comprising ribosome-inactivating proteins

The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.

Method for quantifying LBP in body fluids

The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject.

Method for quantifying BPI in body fluids

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.

Bactericidal/permeability-increasing protein (BPI) deletion analogs

Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.

Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

Fusion proteins and polynucleotides encoding gelonin sequences

Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.

Uses of lipopolysaccharide binding protein

The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.

Proteins encoding gelonin sequences

The present invention provides a crystallized Bactericidal Permeability-Increasing (BPI) protein; methods for x-ray diffraction analysis to provide x-ray diffraction patterns of sufficiently high resolution for three-dimensional structure determination of the protein, as well as methods for rational drug design, based on using amino acid sequence data and/or x-ray crystallography data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms; and atomic coordinates are provided yielding structural information on the lipid binding and lipid transport protein family that includes BPI, LBP, CETP and PLTP.

Growing community of inventors

Walnut Creek, CA, United States of America

Stephen Fitzhugh Carroll